Improvement of plasma biomarkers after switching stroke patients from other angiotensin II type i receptor blockers to olmesartan

Yoshiteru Tada, Kenji Yagi, Masaaki Uno, Nobuhisa Matsushita, Yasuhisa Kanematsu, Kazuyuki Kuwayama, Kenji Shimada, Kyoko Nishi, Motohiro Hirasawa, Junichiro Satomi, Keiko T. Kitazato, Teruyoshi Kageji, Eiji Matsuura, Shinji Nagahiro

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background Managing hypertension is crucial for preventing stroke recurrence. Some stroke patients experience resistant hypertension. In our experimental stroke model, olmesartan increased the expression of angiotensin (Ang) II converting enzyme-2. We hypothesized that switching to olmesartan affects biomarkers and the blood pressure (BP) in stroke patients whose BP is insufficiently controlled by standard doses of Ang II type I receptor blockers (ARBs) other than olmesartan. Methods We recruited 25 patients to study our hypothesis. All had a history of stroke or silent cerebral infarction. We switched them to olmesartan (10-40 mg per day) for 12 weeks and determined their plasma level of Ang-(1-7), peroxiredoxin, oxidized low-density lipoprotein (oxLDL)/β-2-glycoprotein I (β2GPI) complex, adiponectin, high mobility group box 1 (HMGB1), and tumor necrosis factor-α (TNFα) and recorded their BP before and after olmesartan treatment. Results After switching the patients to olmesartan, their plasma level of Ang-(1-7) as a vasoprotective indicator and adiponectin regulating metabolic syndrome was increased, and peroxiredoxin and the oxLDL/β2GPI complex indicating its antioxidative stress and its proatherogenicity were lower than their baseline. This suggests that olmesartan may be more effective than other ARBs to improve these conditions. Neither HMGB1 nor TNFα reflecting an inflammatory response was affected, suggesting that the anti-inflammatory effects of olmesartan are similar to those of other ARBs. The recommended BP (

Original languageEnglish
Pages (from-to)1487-1492
Number of pages6
JournalJournal of Stroke and Cerebrovascular Diseases
Volume24
Issue number7
DOIs
Publication statusPublished - Jul 1 2015

Fingerprint

Angiotensin Receptor Antagonists
Biomarkers
Stroke
Blood Pressure
Peroxiredoxins
Adiponectin
LDL Lipoproteins
Glycoproteins
Tumor Necrosis Factor-alpha
Hypertension
Angiotensin I
olmesartan
Cerebral Infarction
Angiotensin II
Anti-Inflammatory Agents
Theoretical Models
Recurrence

Keywords

  • Adiponectin
  • angiotensin-(1-7)
  • hypertension
  • LDL/β-2-glycoprotein I complex
  • olmesartan
  • peroxiredoxin

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery
  • Rehabilitation
  • Cardiology and Cardiovascular Medicine

Cite this

Improvement of plasma biomarkers after switching stroke patients from other angiotensin II type i receptor blockers to olmesartan. / Tada, Yoshiteru; Yagi, Kenji; Uno, Masaaki; Matsushita, Nobuhisa; Kanematsu, Yasuhisa; Kuwayama, Kazuyuki; Shimada, Kenji; Nishi, Kyoko; Hirasawa, Motohiro; Satomi, Junichiro; Kitazato, Keiko T.; Kageji, Teruyoshi; Matsuura, Eiji; Nagahiro, Shinji.

In: Journal of Stroke and Cerebrovascular Diseases, Vol. 24, No. 7, 01.07.2015, p. 1487-1492.

Research output: Contribution to journalArticle

Tada, Y, Yagi, K, Uno, M, Matsushita, N, Kanematsu, Y, Kuwayama, K, Shimada, K, Nishi, K, Hirasawa, M, Satomi, J, Kitazato, KT, Kageji, T, Matsuura, E & Nagahiro, S 2015, 'Improvement of plasma biomarkers after switching stroke patients from other angiotensin II type i receptor blockers to olmesartan', Journal of Stroke and Cerebrovascular Diseases, vol. 24, no. 7, pp. 1487-1492. https://doi.org/10.1016/j.jstrokecerebrovasdis.2015.03.015
Tada, Yoshiteru ; Yagi, Kenji ; Uno, Masaaki ; Matsushita, Nobuhisa ; Kanematsu, Yasuhisa ; Kuwayama, Kazuyuki ; Shimada, Kenji ; Nishi, Kyoko ; Hirasawa, Motohiro ; Satomi, Junichiro ; Kitazato, Keiko T. ; Kageji, Teruyoshi ; Matsuura, Eiji ; Nagahiro, Shinji. / Improvement of plasma biomarkers after switching stroke patients from other angiotensin II type i receptor blockers to olmesartan. In: Journal of Stroke and Cerebrovascular Diseases. 2015 ; Vol. 24, No. 7. pp. 1487-1492.
@article{15b49f2bdee742f898ac37eecae1a4b4,
title = "Improvement of plasma biomarkers after switching stroke patients from other angiotensin II type i receptor blockers to olmesartan",
abstract = "Background Managing hypertension is crucial for preventing stroke recurrence. Some stroke patients experience resistant hypertension. In our experimental stroke model, olmesartan increased the expression of angiotensin (Ang) II converting enzyme-2. We hypothesized that switching to olmesartan affects biomarkers and the blood pressure (BP) in stroke patients whose BP is insufficiently controlled by standard doses of Ang II type I receptor blockers (ARBs) other than olmesartan. Methods We recruited 25 patients to study our hypothesis. All had a history of stroke or silent cerebral infarction. We switched them to olmesartan (10-40 mg per day) for 12 weeks and determined their plasma level of Ang-(1-7), peroxiredoxin, oxidized low-density lipoprotein (oxLDL)/β-2-glycoprotein I (β2GPI) complex, adiponectin, high mobility group box 1 (HMGB1), and tumor necrosis factor-α (TNFα) and recorded their BP before and after olmesartan treatment. Results After switching the patients to olmesartan, their plasma level of Ang-(1-7) as a vasoprotective indicator and adiponectin regulating metabolic syndrome was increased, and peroxiredoxin and the oxLDL/β2GPI complex indicating its antioxidative stress and its proatherogenicity were lower than their baseline. This suggests that olmesartan may be more effective than other ARBs to improve these conditions. Neither HMGB1 nor TNFα reflecting an inflammatory response was affected, suggesting that the anti-inflammatory effects of olmesartan are similar to those of other ARBs. The recommended BP (",
keywords = "Adiponectin, angiotensin-(1-7), hypertension, LDL/β-2-glycoprotein I complex, olmesartan, peroxiredoxin",
author = "Yoshiteru Tada and Kenji Yagi and Masaaki Uno and Nobuhisa Matsushita and Yasuhisa Kanematsu and Kazuyuki Kuwayama and Kenji Shimada and Kyoko Nishi and Motohiro Hirasawa and Junichiro Satomi and Kitazato, {Keiko T.} and Teruyoshi Kageji and Eiji Matsuura and Shinji Nagahiro",
year = "2015",
month = "7",
day = "1",
doi = "10.1016/j.jstrokecerebrovasdis.2015.03.015",
language = "English",
volume = "24",
pages = "1487--1492",
journal = "Journal of Stroke and Cerebrovascular Diseases",
issn = "1052-3057",
publisher = "W.B. Saunders Ltd",
number = "7",

}

TY - JOUR

T1 - Improvement of plasma biomarkers after switching stroke patients from other angiotensin II type i receptor blockers to olmesartan

AU - Tada, Yoshiteru

AU - Yagi, Kenji

AU - Uno, Masaaki

AU - Matsushita, Nobuhisa

AU - Kanematsu, Yasuhisa

AU - Kuwayama, Kazuyuki

AU - Shimada, Kenji

AU - Nishi, Kyoko

AU - Hirasawa, Motohiro

AU - Satomi, Junichiro

AU - Kitazato, Keiko T.

AU - Kageji, Teruyoshi

AU - Matsuura, Eiji

AU - Nagahiro, Shinji

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Background Managing hypertension is crucial for preventing stroke recurrence. Some stroke patients experience resistant hypertension. In our experimental stroke model, olmesartan increased the expression of angiotensin (Ang) II converting enzyme-2. We hypothesized that switching to olmesartan affects biomarkers and the blood pressure (BP) in stroke patients whose BP is insufficiently controlled by standard doses of Ang II type I receptor blockers (ARBs) other than olmesartan. Methods We recruited 25 patients to study our hypothesis. All had a history of stroke or silent cerebral infarction. We switched them to olmesartan (10-40 mg per day) for 12 weeks and determined their plasma level of Ang-(1-7), peroxiredoxin, oxidized low-density lipoprotein (oxLDL)/β-2-glycoprotein I (β2GPI) complex, adiponectin, high mobility group box 1 (HMGB1), and tumor necrosis factor-α (TNFα) and recorded their BP before and after olmesartan treatment. Results After switching the patients to olmesartan, their plasma level of Ang-(1-7) as a vasoprotective indicator and adiponectin regulating metabolic syndrome was increased, and peroxiredoxin and the oxLDL/β2GPI complex indicating its antioxidative stress and its proatherogenicity were lower than their baseline. This suggests that olmesartan may be more effective than other ARBs to improve these conditions. Neither HMGB1 nor TNFα reflecting an inflammatory response was affected, suggesting that the anti-inflammatory effects of olmesartan are similar to those of other ARBs. The recommended BP (

AB - Background Managing hypertension is crucial for preventing stroke recurrence. Some stroke patients experience resistant hypertension. In our experimental stroke model, olmesartan increased the expression of angiotensin (Ang) II converting enzyme-2. We hypothesized that switching to olmesartan affects biomarkers and the blood pressure (BP) in stroke patients whose BP is insufficiently controlled by standard doses of Ang II type I receptor blockers (ARBs) other than olmesartan. Methods We recruited 25 patients to study our hypothesis. All had a history of stroke or silent cerebral infarction. We switched them to olmesartan (10-40 mg per day) for 12 weeks and determined their plasma level of Ang-(1-7), peroxiredoxin, oxidized low-density lipoprotein (oxLDL)/β-2-glycoprotein I (β2GPI) complex, adiponectin, high mobility group box 1 (HMGB1), and tumor necrosis factor-α (TNFα) and recorded their BP before and after olmesartan treatment. Results After switching the patients to olmesartan, their plasma level of Ang-(1-7) as a vasoprotective indicator and adiponectin regulating metabolic syndrome was increased, and peroxiredoxin and the oxLDL/β2GPI complex indicating its antioxidative stress and its proatherogenicity were lower than their baseline. This suggests that olmesartan may be more effective than other ARBs to improve these conditions. Neither HMGB1 nor TNFα reflecting an inflammatory response was affected, suggesting that the anti-inflammatory effects of olmesartan are similar to those of other ARBs. The recommended BP (

KW - Adiponectin

KW - angiotensin-(1-7)

KW - hypertension

KW - LDL/β-2-glycoprotein I complex

KW - olmesartan

KW - peroxiredoxin

UR - http://www.scopus.com/inward/record.url?scp=84930820228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930820228&partnerID=8YFLogxK

U2 - 10.1016/j.jstrokecerebrovasdis.2015.03.015

DO - 10.1016/j.jstrokecerebrovasdis.2015.03.015

M3 - Article

VL - 24

SP - 1487

EP - 1492

JO - Journal of Stroke and Cerebrovascular Diseases

JF - Journal of Stroke and Cerebrovascular Diseases

SN - 1052-3057

IS - 7

ER -